Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking ...
Notes: 1) Observed values, no imputation for missing data. 2) Includes all participants who met the criteria for MetS at baseline and enough MetS component Week 13 data collected to determine MetS ...
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Viking will add a third ship to sail roundtrip voyages from the Maltese capital city of Valletta, a cultural UNESCO World Heritage Site. Malta also says it is the first European Union country to ...
Viking Therapeutics recently highlighted its obesity program at the 46th Annual William Blair Growth Stock Conference in Chicago and outlined plans to advance VK2735, including both injectable and ...
Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented One presentation will summarize results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results